Benefits from Treatment and Control of Patients with Resistant Hypertension

Table 1

Fatal and nonfatal events at the VA trial in patients with severe hypertension receiving active treatment (HCTZ, reserpine, and hydralazine) or placebo (modified from the VA collaborators [43]).

Events	Active treatment; 𝑛=73	Placebo; 𝑛=70
Deaths	0	4
Stroke	1	4
Coronary events	0	2
Heart failure	0	2
Renal damage	0	2
Accelerated hypertension	0	12